RBC Capital Upgrades Sagent Pharmaceuticals (SGNT) to Outperform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/12/2026
- Wall St set to open higher after inflation data, earnings boost
- Oil prices rise after ship attacks, US-Iran talks deadlock
- CoreWeave soars after fifth straight quarter of record revenue, raised guide
- Four key things investors will watch in Nvidia's earnings next week
- Silver could surge to $90 as investment demand takes over, Citi says
- Lumentum Holdings (LITE) Tops Q4 EPS by 28c, Beats on Revenue; Offers Q1 Guidance
- Aurora Cannabis rejects Curaleaf's unsolicited $4-per-share takeover bid
- AbCellera Biologics (ABCL) PT Raised to $30 at Truist on 'best-in-class potential'
- Wall Street ends down as US-Iran peace optimism fades
- Comscore plans restructuring with $20M-$25M in cost cuts
- After-Hours Movers: CRWV, NBIS, SMCI, LITE, CAVA, HRB
- After-Hours Movers: P, RIOT, BW, RKLB, HIMS, UPWK
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
- After-Hours Movers: SPCX, AMD, ANET, PINS, APPS, UPST, ZETA, BKNG, LCID, CPNG, MTCH
Sagent Pharmaceuticals Reports Second Quarter 2015 Financial Results
August 4, 2015 7:00 AM EDTCompany to evaluate strategic alternatives for Sagent (China) Pharmaceuticals
Company modifies earnings guidance for 2015
SCHAUMBURG, Ill., Aug. 4, 2015 (GLOBE NEWSWIRE) -- Sagent Pharmaceuticals, Inc. (NASDAQ: SGNT), a leader of specialty pharmaceutical products with a specific emphasis on the injectable market, today announced financial results for the quarter ended June 30, 2015.
Second Quarter 2015 Highlights
Revenue increased 12% to $77.3 million driven primarily by the October 1, 2014 acquisition of Omega Laboratories Limited ("Omega"); Reported gross profit declined 18% to $18.4 million, or 23.8% of net revenue;... More